A comprehensive selection of modern antidepressants (SSRIs, SNRIs) utilised to manage depressive disorders, anxiety, and select neuropathic conditions.
Antidepressants are a group of medicines that influence brain chemistry to support emotional balance. They are commonly prescribed when depressive disorders affect daily functioning, mood stability, or sleep quality. Modern formulations include selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine-reuptake inhibitors (SNRIs), among other classes.
In Hong Kong, these agents are part of the public and private health-care services that address mental-health conditions, anxiety-related symptoms, and, in some cases, neuropathic pain. The range of products on the market reflects international regulatory approvals and local prescribing practices.
Typical usage involves a period of several weeks to achieve noticeable improvement, after which the medication may be continued for maintenance. The choice of a specific drug depends on clinical assessment, patient history, and the medication’s safety profile.
Medications such as Escitalopram, Sertraline, and Venlafaxine illustrate the variety of agents that belong to this therapeutic area, while many others share similar mechanisms and clinical goals.
These conditions often coexist, and treating one can alleviate symptoms of another, supporting overall functional recovery.
Each category addresses overlapping symptoms but differs in primary therapeutic intent and pharmacological action.
SSRIs increase serotonin levels by blocking its re-absorption.
SNRIs raise both serotonin and norepinephrine activity.
TCAs affect several neurotransmitters and are older agents in the class.
These drugs have unique mechanisms beyond serotonin or norepinephrine re-uptake inhibition.
Antidepressants aim to restore the balance of neurotransmitters that regulate mood, anxiety, and pain perception. Treatment typically begins with a low dose that is gradually increased to a therapeutic level, a process managed by qualified clinicians.
Most agents are taken orally, once or twice daily, and may require several weeks before therapeutic effects become evident. Long-term use is common when the underlying condition is chronic, while some patients transition off medication after sustained improvement.
Understanding the distinction between acute treatment (initial symptom relief) and maintenance therapy (preventing relapse) helps patients set realistic expectations about the course of care.
These scenarios reflect typical patterns observed in Hong Kong’s healthcare settings, where mental-health services integrate both public hospitals and private practitioners.
Selective serotonin-reuptake inhibitor (SSRI): A drug that blocks the re-absorption of serotonin, increasing its availability in the brain.
Serotonin-norepinephrine-reuptake inhibitor (SNRI): A medication that inhibits the re-uptake of both serotonin and norepinephrine, enhancing mood-regulating signals.
Tricyclic antidepressant (TCA): An older class of antidepressants that affect multiple neurotransmitters and are often used when newer agents are unsuitable.
Atypical antidepressant: An antidepressant with a mechanism that does not fit the classic SSRI or SNRI profile.
Therapeutic dose: The amount of medication that has been shown to produce the desired clinical effect in most patients.
This category presents a comprehensive clinical overview of therapeutics associated with Antidepressants, including both indicated and off-label applications. Off-label use refers to the medical practice of utilizing authorized medications for conditions outside their primary regulatory approval. This information is provided for educational completeness and does not constitute medical advice, endorsement, or a recommendation. We disclaim all liability for the clinical application of listed treatments. Patients must consult a licensed healthcare professional and review specific product labeling for definitive guidance on safety, efficacy, and dosage.
Antidepressants are prescribed to alleviate symptoms of depression, various anxiety disorders, and certain types of chronic nerve-related pain.
Most individuals notice an improvement after several weeks of consistent use, although the exact timeline varies.
Yes. The main groups include SSRIs, SNRIs, tricyclic antidepressants, and atypical agents, each with a distinct mechanism of action.
Interactions are possible, and clinicians assess medication histories to minimise risk.
Response rates differ; some patients achieve full remission, while others may need an alternative medication or adjunct therapy.
Generic names identify the active ingredient, whereas brand names are marketed by specific manufacturers.
They are available as oral tablets, capsules, and, for a few agents, liquid suspensions.
Certain agents are listed on the Hospital Authority formulary, while others may be accessed through private prescriptions.
Some agents, such as low-dose trazodone, are sometimes employed for sleep disturbances linked to mood disorders.
Acute therapy targets the initial reduction of symptoms, whereas maintenance therapy aims to sustain improvement and prevent relapse.
